NovaMed gets rights to EUSA's Erwinase for leukemia
Executive Summary
Specialty pharmaco EUSA has granted NovaMed (in-licenses cancer, cardiovascular, CNS, and urology therapeutics) exclusive rights to sell its Erwinase (crisantaspase) in China.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice